Literature DB >> 35812021

Managing IBD in patients with previous cancers.

Sarah E Minnis-Lyons1, Zara Aiken1, Shien Chow2, Shahida Din3.   

Abstract

A frequent dilemma faced in the inflammatory bowel disease (IBD) clinic is how to best treat a patient with a previous cancer diagnosis. The changing demographics of our patient population will make this quandary more common. Previous guidance has emphasised the importance of lengthy postcancer drug holidays and cautious use of IBD therapies. However, accumulating evidence suggests this approach may be unnecessarily conservative. This review considers recent evidence on the safety of IBD drugs, cancer and recurrent cancer risk in patients with IBD and provides a framework for shared decision making involving patient, gastroenterologist and oncologist. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  adverse drug reactions; cancer; clinical decision making; inflammatory bowel disease

Year:  2022        PMID: 35812021      PMCID: PMC9234723          DOI: 10.1136/flgastro-2022-102187

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  64 in total

1.  Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.

Authors:  Bruce E Sands; William J Sandborn; Remo Panaccione; Christopher D O'Brien; Hongyan Zhang; Jewel Johanns; Omoniyi J Adedokun; Katherine Li; Laurent Peyrin-Biroulet; Gert Van Assche; Silvio Danese; Stephan Targan; Maria T Abreu; Tadakazu Hisamatsu; Philippe Szapary; Colleen Marano
Journal:  N Engl J Med       Date:  2019-09-26       Impact factor: 91.245

2.  STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.

Authors:  Dan Turner; Amanda Ricciuto; Ayanna Lewis; Ferdinando D'Amico; Jasbir Dhaliwal; Anne M Griffiths; Dominik Bettenworth; William J Sandborn; Bruce E Sands; Walter Reinisch; Jürgen Schölmerich; Willem Bemelman; Silvio Danese; Jean Yves Mary; David Rubin; Jean-Frederic Colombel; Laurent Peyrin-Biroulet; Iris Dotan; Maria T Abreu; Axel Dignass
Journal:  Gastroenterology       Date:  2021-02-19       Impact factor: 22.682

Review 3.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

4.  Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.

Authors:  Halima Cheddani; Luc Dauchet; Mathurin Fumery; Cloé Charpentier; Anne Marie Bouvier; Jean-Louis Dupas; Benjamin Pariente; Laurent Peyrin-Biroulet; Guillaume Savoye; Corinne Gower-Rousseau
Journal:  Am J Gastroenterol       Date:  2016-08-02       Impact factor: 10.864

5.  Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.

Authors:  Steven R Ytterberg; Deepak L Bhatt; Ted R Mikuls; Gary G Koch; Roy Fleischmann; Jose L Rivas; Rebecca Germino; Sujatha Menon; Yanhui Sun; Cunshan Wang; Andrea B Shapiro; Keith S Kanik; Carol A Connell
Journal:  N Engl J Med       Date:  2022-01-27       Impact factor: 91.245

6.  Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

Authors:  Laurent Beaugerie; Nicole Brousse; Anne Marie Bouvier; Jean Frédéric Colombel; Marc Lémann; Jacques Cosnes; Xavier Hébuterne; Antoine Cortot; Yoram Bouhnik; Jean Pierre Gendre; Tabassome Simon; Marc Maynadié; Olivier Hermine; Jean Faivre; Fabrice Carrat
Journal:  Lancet       Date:  2009-11-07       Impact factor: 79.321

7.  Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data.

Authors:  Timothy Card; Ryan Ungaro; Fatima Bhayat; Aimee Blake; Gary Hantsbarger; Simon Travis
Journal:  Aliment Pharmacol Ther       Date:  2019-11-20       Impact factor: 8.171

8.  Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study.

Authors:  Henrik Toft Sørensen; Lene Mellemkjaer; Gunnar Lauge Nielsen; John A Baron; Jørgen H Olsen; Margaret R Karagas
Journal:  J Natl Cancer Inst       Date:  2004-05-05       Impact factor: 13.506

9.  Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.

Authors:  Gary R Lichtenstein; Gerhard Rogler; Matthew A Ciorba; Chinyu Su; Gary Chan; Ronald D Pedersen; Nervin Lawendy; Daniel Quirk; Chudy I Nduaka; Andrew J Thorpe; Julian Panés
Journal:  Inflamm Bowel Dis       Date:  2021-05-17       Impact factor: 5.325

Review 10.  Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines.

Authors:  Ross J Porter; Mark J Arends; Antonia M D Churchhouse; Shahida Din
Journal:  J Crohns Colitis       Date:  2021-12-18       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.